StockData

Nutex Health Inc. (NUTX) stock analysis

NUTXNasdaqServices-Business Services, NECFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/3067% below fair value
$189.19+2.94 (+1.58%)

Close on Nov 11, 2026Market cap $1.30BP/E 8.1Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value4Growth2Performance4Health5Dividend0

Solid15 of 30 checks passed

Nutex Health passes 15 of the 30 checks behind our score; 9 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
4/6
Growth
2/6
Past performance
4/6
Financial health
5/6
Dividend
0/6

What stands out

  • Margin of safety over 20%

    The price is 66.8% below fair value, more than the 20% cushion we look for.

  • Trading below fair value

    The share price of $189.19 is below our fair value estimate of $570.15.

  • Return on capital over 10%

    Return on invested capital was 117%, above the 10% that usually covers the cost of capital.

  • Low debt

    Debt is 9.7% of shareholders' equity, under the 40% we consider low.

What to watch

  • Return on equity under 15%

    Return on equity was 43.8% over the last twelve months and averaged -28.8% over five years; we look for 15% on both.

  • Earnings shrank over 5 years

    Net income shrank 7.8% a year on average over the last five fiscal years.

  • P/B above the industry

    Nutex Health's price-to-book of 2.97 is above the Miscellaneous Business Services median of 2.48.

  • Growing slower than the industry

    Revenue grew -18.8% over the last twelve months; the Miscellaneous Business Services median is 9.9%.

Valuation4/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E below the industry

    Nutex Health's P/E of 8.1 is below the Miscellaneous Business Services median of 25.8.

  • EV/EBITDA below its 5-year median

    Nutex Health's EV/EBITDA of 3.6 is below its 5-year median of 4.9.

  • P/B above the industry

    Nutex Health's price-to-book of 2.97 is above the Miscellaneous Business Services median of 2.48.

  • Trading below fair value

    The share price of $189.19 is below our fair value estimate of $570.15.

  • Margin of safety over 20%

    The price is 66.8% below fair value, more than the 20% cushion we look for.

Growth2/6

  • Revenue growing 10%+ a year

    Revenue grew 58.6% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings growth accelerating

    Net income grew 36.5% over the last twelve months, against a 5-year average of -7.8% a year.

  • Growing slower than the industry

    Revenue grew -18.8% over the last twelve months; the Miscellaneous Business Services median is 9.9%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin slipping

    Gross margin was 47.8% over the last twelve months, against 55.0% a year earlier.

Past performance4/6

  • Return on equity under 15%

    Return on equity was 43.8% over the last twelve months and averaged -28.8% over five years; we look for 15% on both.

  • Return on capital over 10%

    Return on invested capital was 117%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Nutex Health's return on equity of 43.8% is above the Miscellaneous Business Services median of 6.8%.

  • Earnings shrank over 5 years

    Net income shrank 7.8% a year on average over the last five fiscal years.

  • Net margin above its 5-year average

    Net margin was 20.7% over the last twelve months, against a 5-year average of -30.7%.

  • Net margin above the industry

    Nutex Health's net margin of 20.7% is above the Miscellaneous Business Services median of 3.8%.

Financial health5/6

  • Low debt

    Debt is 9.7% of shareholders' equity, under the 40% we consider low.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 611% of total debt.

  • Interest well covered

    Operating income covers interest expense 16.2 times.

  • Short-term assets cover short-term debts

    Current assets are 4.76 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 3.75; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Nutex Health has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$570.15

The share price is 67% below this estimate.

20%+ below
Near fair value
20%+ above
$189.19Price$570.15Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E25.8×–25.8×$601.8853%
EV/EBITDA10.4×4.9×15.7×$533.8847%
Earnings powerleft out, too far from the others14.2% cost of equity––$88.69–
Fair value$570.15100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Miscellaneous Business Services median 25.8

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$29.41M
Value traded per 1% price move
$10.16M

Downside

High risk

Typical loss in a bad month
39.6%
Volatility (annualized)
91%
Sharpe ratio, 1 year
0.60
Beta to the S&P 500 (5Y)
1.86

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

50.8%−6.8 pts over 5 years

Operating margin

31.5%−24.4 pts over 5 years

Net margin

8.1%−30.6 pts over 5 years

See a number that looks wrong?